Phase II
A number of companies reported clinical trial data last week. Here’s a look.
Evotec SE announced that the Company has been informed by Bayer about positive Phase IIa results from a study surveying the safety, efficacy and dosage of the compound BAY1817080 in refractory chronic cough.
FGFR inhibitor gains FDA approval based on 40% response rate in MD Anderson-led Phase II trial
Arcutis, Inc., a privately held immuno-dermatology drug development company addressing significant unmet needs in dermatology, announced positive top line results for its Phase 2b study evaluating ARQ-151 as a potential topical treatment for plaque psoriasis.
Here’s a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
InflaRx reported additional in-depth analysis of the completed double blind, placebo controlled part of the ongoing international SHINE Phase IIb study to supplement InflaRx’s top line disclosure of results reported on June 5, 2019.
In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
More than 600 employees will lose their jobs as the companies reshape their corporate strategies.
PRESS RELEASES